Login to Your Account

Other News To Note

Friday, July 29, 2011
Soligenix Inc., of Princeton, N.J., expanded its North American licensing partnership with Sigma-Tau Pharmaceuticals Inc., of Rome, for the development and commercialization of orBec (oral beclomethasone dipropionate) in Europe. The amended agreement includes a $5 million up-front payment to Soligenix, along with a possible $11 million in milestones and 40 percent royalties on net sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription